<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="other" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">938</journal-id><journal-id journal-id-type="pmc-domain">ijpsych</journal-id><journal-id journal-id-type="publisher-id">IJPsy</journal-id><journal-id journal-id-type="publisher-id">Indian J Psychiatry</journal-id><journal-title-group><journal-title>Indian Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0019-5545</issn><issn pub-type="epub">1998-3794</issn><publisher><publisher-name>Wolters Kluwer -- Medknow Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11964174</article-id><article-id pub-id-type="pmcid-ver">PMC11964174.1</article-id><article-id pub-id-type="pmcaid">11964174</article-id><article-id pub-id-type="pmcaiid">11964174</article-id><article-id pub-id-type="pmid">40181877</article-id><article-id pub-id-type="doi">10.4103/indianjpsychiatry.indianjpsychiatry_794_24</article-id><article-id pub-id-type="publisher-id">IJPsy-67-256</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Brief Research Communication</subject></subj-group></article-categories><title-group><article-title>Tapentadol as a drug of abuse &#8211; A preliminary report</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Shivaprakash</surname><given-names initials="P">Prakrithi</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Shukla</surname><given-names initials="L">Lekhansh</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Joshi</surname><given-names initials="S">Sourabh</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mahadevan</surname><given-names initials="J">Jayant</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kandasamy</surname><given-names initials="A">Arun</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chand</surname><given-names initials="PK">Prabhat K.</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Benegal</surname><given-names initials="V">Vivek</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Murthy</surname><given-names initials="P">Pratima</given-names></name><xref rid="aff1" ref-type="aff"/></contrib></contrib-group><aff id="aff1">Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, Karnataka, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Lekhansh Shukla, Office of the Centre for Addiction Medicine, 2<sup>nd</sup> floor, Centre for Addiction Medicine Ward &#8211; Female wing, Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru - 560 029, Karnataka, India. E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="drlekhansh@gmail.com">drlekhansh@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>19</day><month>2</month><year>2025</year></pub-date><volume>67</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">485842</issue-id><fpage>256</fpage><lpage>259</lpage><history><date date-type="received"><day>12</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-04 16:25:24.827"><day>04</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright: &#169; 2025 Indian Journal of Psychiatry</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="IJPsy-67-256.pdf"/><abstract><sec id="st1"><title>Background:</title><p>Tapentadol is a dual action opioid analgesic with emerging data on abuse and diversion.</p></sec><sec id="st2"><title>Aim:</title><p>This study describes tapentadol abuse, clinical presentation, and treatment patterns.</p></sec><sec id="st3"><title>Methods:</title><p>We reviewed patients seeking help for tapentadol use (2017&#8211;2023) at a South Indian tertiary hospital. We collected data on sociodemographics, clinical profiles, and treatment, including buprenorphine dose and dose limiting side effects.</p></sec><sec id="st4"><title>Results:</title><p>Of 933 opioid use disorder cases, 228 involved tapentadol. Most (89%) initiated opioid use with tapentadol, and 93% injected dissolved tablets. 80% were diagnosed with opioid dependence. Over half required inpatient treatment. 75% received buprenorphine, but tolerability was poor. The median first day dose was 0.8 mg (IQR = 0.4&#8211;2), and the maintenance dose was 4 mg (IQR = 2&#8211;8), with nausea being the main side effect.</p></sec><sec id="st5"><title>Conclusion:</title><p>We can conclude that Tapentadol is prone to abuse and dependence. These patients have poor buprenorphine tolerability and receive low maintenance doses. Further research is needed on effective opioid agonist treatment for tapentadol dependence.</p></sec></abstract><kwd-group><kwd>Buprenorphine</kwd><kwd>opiate substitution treatment</kwd><kwd>opioid-related disorders</kwd><kwd>people who inject drugs</kwd><kwd>Tapentadol</kwd></kwd-group><funding-group><funding-statement>LS, PS and PM received funding in April 2023 from the National Fund for Control of Drug Abuse, Department of Revenue, Ministry of Finance, Government of India (Sanction Order No. 35, dated 25<sup>th</sup> April 2023) to conduct hospital and community-based research in Tapentadol abuse.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Tapentadol, a dual-action analgesic, combines &#181;-opioid receptor (MOR) agonism with norepinephrine reuptake inhibition. Both oral and recently nasal spray formulations of tapentadol have been available in many Asian countries, United States, Australia, and Europe for over a decade. Tapentadol&#8217;s MOR affinity is approximately 300 times that of tramadol.[<xref rid="R1" ref-type="bibr">1</xref>] Since abuse potential of opioids is linked to MOR activation, one would expect tapentadol to have a higher abuse liability. Contrary to this, the last updated review by the World Health Organization Expert Committee on Drug Dependence did not conclude on international scheduling of tapentadol and kept it under surveillance.[<xref rid="R2" ref-type="bibr">2</xref>] In fact, researchers from other countries (United States of America) have found that tapentadol is rarely abused.[<xref rid="R3" ref-type="bibr">3</xref>]</p><p>However, abuse of a particular opioid differs between regions depending on availability of various prescription drugs, abuse deterrent preparations, and illicit opioids. We have earlier reported rising popularity of tapentadol as a drug of abuse in India.[<xref rid="R4" ref-type="bibr">4</xref>] In this report, we provide a fuller description of this phenomenon including details of treatment utilization.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><p>We have maintained a registry of all patients seeking help to stop tapentadol use since 2017. This study reports the findings of clinical records review of these patients.</p><p>We report findings from a tertiary-level, teaching hospital from southern India with a dedicated addiction medicine unit. The center has an 80-bed ward with subsidized treatment for poor patients. Outpatient treatment is available thrice a week along with opioid agonist treatment (OAT) in the form of sublingual buprenorphine-naloxone (4:1) tablets. All patients are seen by at least two qualified psychiatrists, and the diagnoses are made according to International Classification of Diseases Version-10 criteria. The choice of treatment for opioid use disorder (OAT vs naltrexone) is made in consultation with the patient, and we suggest OAT for People Who Inject Drugs (PWIDs). Patients are inducted to OAT with lower doses, adjusted based on tolerability and control of craving.</p><p>This study includes all adult patients who sought help for controlling tapentadol use from January 1, 2017 to January 31, 2023. Two authors (PS and LS) have reviewed medical records of all these cases to extract the following information:</p><p>
<list list-type="order"><list-item><p>Sociodemographic: Age, sex, economic status, occupation, and marital status.</p></list-item><list-item><p>Substance Use History: Lifetime and current use of substances and age at first use.</p></list-item><list-item><p>Opioid Use: Lifetime and current use of opioids (including tapentadol), route, and frequency of use in the past 3 months.</p></list-item><list-item><p>Clinical course: Locus of care &#8211; outpatient or inpatient, number of hospital visits in the first 6 months, opioid withdrawal symptoms noted by the treating psychiatrist, receipt and maximum dose of OAT received, and dose-limiting adverse effects of OAT. We also noted the starting dose of buprenorphine (total received in the first 24 hours) and number of days to reach the maximum dose.</p></list-item></list>
</p><p>The study received approval from the Institution Ethics Committee.</p></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>Between January 2017 and January 2023, we had 933 cases of opioid use disorder (F11, Mental and Behavioural Disorders due to use of Opioids), out of which 228 reported tapentadol as the primary drug used. All 228 registered after February 2017. There is a steady increase in the number of patients seeking help for controlling tapentadol use from 14 in 2017 to 87 in 2022 except for 2020 due to COVID-related restrictions.</p><p>A typical patient is school-educated, single, young, and male from economically disadvantaged sections of the society [<xref rid="indianjpsychiatry.indianjpsychiatry_794_24-T1" ref-type="table">Table 1</xref>]. More than one-third of these patients (90, 39.4%) reported tapentadol as the first habit-forming substance in their life (excluding tobacco and caffeine), half of them (121, 51%) had tried alcohol and cannabis before opioids, and the rest reported exposure to stimulants and sedatives before opioids. A majority of tapentadol users (203, 89%) had never used any other opioid. Among those who had, 21 reported moving from another opioid to tapentadol and only four reported trying other opioids after the onset of tapentadol use. All patients reported exclusively using tapentadol (among opioids) in the past 3 months.</p><table-wrap position="float" id="indianjpsychiatry.indianjpsychiatry_794_24-T1" orientation="portrait"><label>Table 1</label><caption><p>Clinical and sociodemographic characteristics of tapentadol users and other opioid users</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">Tapentadol (<italic toggle="yes">n</italic>=228)</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Age at first presentation in years, median [Inter Quartile Range (IQR)]</td><td align="center" rowspan="1" colspan="1">23 (21-26)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at first substance use excluding tobacco, median (IQR)</td><td align="center" rowspan="1" colspan="1">17 (16-20)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at onset of opioid use, median (IQR)</td><td align="center" rowspan="1" colspan="1">21 (18-24)</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of tapentadol use in years, median (IQR)</td><td align="center" rowspan="1" colspan="1">2 (1-3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Route of tapentadol use=Injections, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">213 (93%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Current substance use<sup>#</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Cannabinoids</td><td align="center" rowspan="1" colspan="1">107 (46.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Alcohol</td><td align="center" rowspan="1" colspan="1">52 (22.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Sedative/hypnotics</td><td align="center" rowspan="1" colspan="1">38 (16.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Other stimulants</td><td align="center" rowspan="1" colspan="1">23 (10.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender &#8211; Female, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">8 (3.5%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Marital status, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Married</td><td align="center" rowspan="1" colspan="1">56 (25%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Never married</td><td align="center" rowspan="1" colspan="1">171 (75%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Divorced/separated/widowed</td><td align="center" rowspan="1" colspan="1">1 (0.4%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Educational status, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;No formal education</td><td align="center" rowspan="1" colspan="1">9 (3.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;School education</td><td align="center" rowspan="1" colspan="1">130 (57%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;College education</td><td align="center" rowspan="1" colspan="1">89 (39%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Occupational status, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Professional</td><td align="center" rowspan="1" colspan="1">8 (3.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Clerical, shop owner, farmer</td><td align="center" rowspan="1" colspan="1">22 (9.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Skilled worker</td><td align="center" rowspan="1" colspan="1">67 (29%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Semiskilled worker</td><td align="center" rowspan="1" colspan="1">29 (13%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Unskilled worker</td><td align="center" rowspan="1" colspan="1">37 (16%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Unemployed</td><td align="center" rowspan="1" colspan="1">65 (29%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Economic status &#8211; Below Poverty Line, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">149 (65%)</td></tr></tbody></table><table-wrap-foot><fn id="fn-T1-1"><p><sup>#</sup>Use in the past 3 months</p></fn></table-wrap-foot></table-wrap><p>All but 15 patients reported using tapentadol by dissolving the tablets in normal saline or distilled water and injecting the solution. All these PWIDs (n = 213) reported injecting daily with a median frequency of 8 injections per day (IQR = 6&#8211;9, maximum = 14). These patients were exposed to a median dose of 800 mg of tapentadol (IQR = 600&#8211;900, maximum = 1600) daily via the injection route.</p><p>The majority of these patients (180, 78.9%) were diagnosed as opioid dependence syndrome (F11.2), and the rest met the threshold for harmful use (F11.1). In terms of cardinal symptoms, intense craving was the most frequent reported (179, 78.5%), followed by loss of control (177, 77.6%), tolerance (174, 76.3%), and continued use despite physical harm (157, 68.9%). Withdrawal symptoms were reported or observed in all patients with restlessness being the most common (216, 94.7%), followed by muscle pain (198, 86.8%) and nasal congestion or discharge (172, 75.4%). Mydriasis was noted in 168 (73.7%) patients.</p><p>The treatment utilization in the first 6 months is as follows: A small percentage of patients (25, 10.9%) only had one contact in the outpatient department and did not return after that. For the remainder, the median number of hospital visits is 6 (IQR = 3&#8211;12). More than half of the patients received inpatient treatment (136, 59.6%), most among them requiring readmission within 6 months (123, 90.4%).</p><p>Most of the patients received buprenorphine (172, 75.4%). Among these patients, the median dose of buprenorphine in the first 24 hours is 0.8 mg (IQR = 0.4&#8211;2). Most of these patients received low doses even during the maintenance phase; the median of maximum dose of buprenorphine is 4 mg (IQR = 2&#8211;8). It took almost a week to reach the final dose (median = 6 days, IQR = 2&#8211;10). Notably, more than one third of the patients (n = 68, 39.5%) could not tolerate even 4 mg of buprenorphine despite a long titration phase. Among the adverse effects which limited dose increase in the first week, nausea and vomiting were most common (n = 159, 92.4%).</p></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>The findings of this study allow us to draw two main conclusions. First, tapentadol tablets are liable to be abused and can result in opioid dependence. Tapentadol users have poor tolerability to buprenorphine and receive low doses during the maintenance phase.</p><p>In India, the Central Drugs Standard Control Organisation (CDSCO) approved tapentadol for moderate to severe acute pain in adults in 2011[<xref rid="R5" ref-type="bibr">5</xref>] and it was restricted to prescription-only under Schedule H1 in 2021.[<xref rid="R6" ref-type="bibr">6</xref>] Tapentadol prescriptions have grown rapidly in developed[<xref rid="R7" ref-type="bibr">7</xref>] as well as developing countries.[<xref rid="R8" ref-type="bibr">8</xref>] Despite research suggesting low abuse potential, reports of trafficking across international borders[<xref rid="R9" ref-type="bibr">9</xref>] and seizures[<xref rid="R10" ref-type="bibr">10</xref>] indicate a rising problem with tapentadol abuse in different parts of the world. Our findings demonstrate tapentadol&#8217;s potential to rapidly attract new users and cause OUD. Many tapentadol preparations available in India are easily crushed, dissolved in water, drawn into syringes, and self-administered intravenously.[<xref rid="R4" ref-type="bibr">4</xref>]</p><p>Most tapentadol users in the study had opioid dependence, with the remainder experiencing harmful use. They sought medical treatment within a median of 2 years of starting use &#8211; in our experience, primarily due to injection site complications and withdrawal symptoms. There was intensive treatment utilization, with more than half of them receiving inpatient care and many of them readmitted within 6 months. In view of injecting drug use (IDU) and typical withdrawal symptoms, most patients received buprenorphine for both detoxification and long-term treatment. This is an off-label use of sublingual buprenorphine, and we learned a few lessons. Most patients could not tolerate an evidence-based dose of buprenorphine due to nausea, dizziness, and constipation. In effect, we have a situation where patients have all symptoms of opioid dependence, including withdrawal, but poor tolerance to potent long-acting agents. This presents a dual challenge as OAT is the only evidence-based harm reduction measure for opioid-using PWIDs. This inadequate dosing of buprenorphine due to poor tolerability is likely a major factor in relapse and need for readmissions.</p><p>We see a particular typology of tapentadol users. Most belong to vulnerable groups &#8211; young, less educated, economically disadvantaged, with concurrent use of other substances &#8211; cannabis, stimulants, alcohol, and sedative hypnotics. These patients transitioned from occasional drug use (mostly cannabis) to injecting tapentadol, with tapentadol being their introduction to opioid use. The reason for popularity of injection use of tapentadol in this group is unclear, especially since this region has not historically had a high prevalence of IDU. For instance, the state of Karnataka had an estimated 44,530 PWIDs in 2019,[<xref rid="R11" ref-type="bibr">11</xref>] while the estimated population is over three times that of Australia. Notably, most tapentadol users are PWIDs, and the higher treatment burden in this group is likely due to IDU rather than some peculiarity of the molecule itself.</p><p>Our findings suffer from two main limitations. First, they cannot be generalized to non-treatment-seeking populations. However, this being a new drug, community-based studies are lacking, and we have limited our inferences to treatment-seeking patients. Second, these findings rely on a small sample of 228 patients from a particular center; thus, the conclusions should be considered preliminary and are reported as such. Empirical studies are needed to determine effective dosing and tolerability of OAT in tapentadol dependence.</p><sec id="sec2-1"><title>Key messages</title><p>
<list list-type="bullet"><list-item><p>Tapentadol tablets without any abuse-deterrent formulation are liable to be abused.</p></list-item><list-item><p>Most tapentadol users (93%) reported using it via an injection route.</p></list-item><list-item><p>Most did not receive adequate doses of buprenorphine for opioid agonist treatment.</p></list-item><list-item><p>Tapentadol users were more likely to need hospitalization than other opioid users.</p></list-item></list>
</p></sec><sec sec-type="COI-statement" id="sec2-3"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Faria</surname><given-names>J</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>J</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>R</given-names></name><name name-style="western"><surname>Queir&#243;s</surname><given-names>O</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>F</given-names></name><name name-style="western"><surname>Dinis-Oliveira</surname><given-names>RJ</given-names></name></person-group><article-title>Comparative pharmacology and toxicology of tramadol and tapentadol</article-title><source>Eur J Pain</source><year>2018</year><volume>22</volume><fpage>827</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">29369473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ejp.1196</pub-id></element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="book" publication-format="print"><person-group person-group-type="author"><collab>World Health Organisation</collab></person-group><article-title>WHO Expert Committee on Drug Dependence - Thirty sixth report</article-title><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organisation</publisher-name><year>2015</year><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ecddrepository.org/en/tapentadol">https://ecddrepository.org/en/tapentadol</uri>. [Last accessed on 2024 Sep 12]</comment><pub-id pub-id-type="pmid">26062388</pub-id></element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Rzetelny</surname><given-names>A</given-names></name><name name-style="western"><surname>Meske</surname><given-names>D</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P</given-names></name><name name-style="western"><surname>Passik</surname><given-names>S</given-names></name></person-group><article-title>Tapentadol is the least common opioid found in admission urine drug-test results at an intensive outpatient opioid-use disorder treat-ment program in Ohio: A brief report</article-title><source>J Opioid Manag</source><year>2021</year><volume>17</volume><fpage>13</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">33735424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5055/jom.2021.0610</pub-id></element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>D</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>L</given-names></name><name name-style="western"><surname>Saha</surname><given-names>P</given-names></name><name name-style="western"><surname>Mahadevan</surname><given-names>J</given-names></name><name name-style="western"><surname>Kandasamy</surname><given-names>A</given-names></name><name name-style="western"><surname>Chand</surname><given-names>P</given-names></name><etal/></person-group><article-title>Tapentadol abuse and dependence in India</article-title><source>Asian J Psychiatr</source><year>2020</year><volume>49</volume><fpage>101978</fpage><comment>doi: 10.1016/j.ajp.2020.101978</comment><pub-id pub-id-type="pmid">32120298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajp.2020.101978</pub-id></element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="webpage" publication-format="web"><person-group person-group-type="author"><collab>Central Drugs Standard Control Organisation</collab></person-group><article-title>New Drugs Approved by CDSCO: Central Drugs Standard Control Organisation</article-title><year>2011</year><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cdscoonline.gov.in/CDSCO/Drugs">https://cdscoonline.gov.in/CDSCO/Drugs</uri>. [Last accessed on 2024 Mar 22]</comment></element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="book" publication-format="print"><person-group person-group-type="author"><collab>Central Drugs Standard Control Organisation</collab></person-group><article-title>Inclusion of Tapentadol in Schedule H1 at Serial Number 48</article-title><publisher-loc>New Delhi</publisher-loc><publisher-name>The Controller of Publications, Delhi</publisher-name><year>2021</year><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NzE0MA==">https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NzE0MA==</uri>. [Last accessed on 2024 Sep 09]</comment></element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="book" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Chrzanowska</surname><given-names>A</given-names></name><name name-style="western"><surname>Gisev</surname><given-names>N</given-names></name><name name-style="western"><surname>Price</surname><given-names>O</given-names></name><name name-style="western"><surname>Sutherland</surname><given-names>R</given-names></name><name name-style="western"><surname>Memedovic</surname><given-names>S</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></name><etal/></person-group><article-title>Tapentadol use and harms in Australia: Analysis of opioid sales data and sentinel survey data from people who inject drugs</article-title><publisher-loc>Sydney</publisher-loc><publisher-name>National Drug and Alcohol Research Centre, University of New South Wales</publisher-name><year>2020</year><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ndarc.med.unsw.edu.au/resource/tapentadol-use-and-harms-australia-analysis-opioid-sales-data-and-sentinel-survey-data#:~:text=Tapentadol%20is%20a%20centrally%2Dacting,lower%20abuse%20potential%20%5B3%5D">https://ndarc.med.unsw.edu.au/resource/tapentadol-use-and-harms-australia-analysis-opioid-sales-data-and-sentinel-survey-data#:~:text=Tapentadol%20is%20a%20centrally%2Dacting, lower%20abuse%20potential%20%5B3%5D</uri>. [Last accessed on 2024 Sep 09]</comment></element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jayawardana</surname><given-names>S</given-names></name><name name-style="western"><surname>Forman</surname><given-names>R</given-names></name><name name-style="western"><surname>Johnston-Webber</surname><given-names>C</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>A</given-names></name><name name-style="western"><surname>Berterame</surname><given-names>S</given-names></name><name name-style="western"><surname>de Joncheere</surname><given-names>C</given-names></name><etal/></person-group><article-title>Global consumption of prescription opioid analgesics between 2009-2019: A country-level observational study</article-title><source>EClinicalMedicine</source><year>2021</year><volume>42</volume><fpage>101198</fpage><comment>doi: 10.1016/j.eclinm.2021.101198</comment><pub-id pub-id-type="pmid">34820610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2021.101198</pub-id><pub-id pub-id-type="pmcid">PMC8599097</pub-id></element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="book" publication-format="print"><person-group person-group-type="author"><collab>International Narcotics Control Board</collab></person-group><article-title>INCB Operation New Horizons identifies new trafficking in tapentadol, an emerging synthetic opioid</article-title><publisher-loc>Vienna</publisher-loc><publisher-name>International Narcotics Control Board</publisher-name><year>2021</year><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.incb.org/incb/en/news/news_2021/incb-operation-new-horizons-identifies-new-trafficking-in-tapentadol--an-emerging-synthetic-opioid.html">https://www.incb.org/incb/en/news/news_2021/incb-operation-new-horizons-identifies-new-trafficking-in-tapentadol--an-emerging-synthetic-opioid.html</uri>. [Last accessed on 2024 Sep 09]</comment></element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="book" publication-format="print"><person-group person-group-type="author"><collab>U.S. Customs and Border Protection</collab></person-group><article-title>Opioids and Pain Pills Flood International Mail Facility at O&#8217;Hare</article-title><publisher-loc>Chicago</publisher-loc><publisher-name>U.S. Department of Homeland Security</publisher-name><year>2021</year><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cbp.gov/newsroom/local-media-release/opioids-pain-pills-flood-international-mail-facility-o-hare">https://www.cbp.gov/newsroom/local-media-release/opioids-pain-pills-flood-international-mail-facility-o-hare</uri>. [Last accessed on 2024 Apr 20]</comment></element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="book" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ambekar</surname><given-names>A</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></name><name name-style="western"><surname>Rao</surname><given-names>R</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>AK</given-names></name><name name-style="western"><surname>Khandelwal</surname><given-names>SK</given-names></name><name name-style="western"><surname>Chadda</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Magnitude of Substance Use in India</article-title><publisher-loc>New Delhi</publisher-loc><publisher-name>Ministry of Social Justice and Empowerment, Government of India</publisher-name><year>2019</year><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://socialjustice.nic.in/writereaddata/UploadFile/Magnitude_Substance_Use_India_REPORT.pdf">http://socialjustice.nic.in/writereaddata/UploadFile/Magnitude_Substance_Use_India_REPORT.pdf</uri>. [Last accessed on 2024 Apr 20]</comment></element-citation></ref></ref-list></back></article></pmc-articleset>